NEW YORK (GenomeWeb) – French companion diagnostics firm ImmunID announced today that it has signed a deal with Memorial Sloan Kettering Cancer Center (MSKCC) to clinically validate its ImmunTracker assay as a predictor of patient response to cancer immunotherapy.

ImmunTracker is a PCR-based system that detects gene recombinations in T cells, providing data about how a cancer patient's immune system is responding to a particular immunotherapy. In collaboration with MSKCC, ImmunID aims to test the assay in solid tumor patients being treated with immune checkpoint inhibitors.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.

Sponsored by

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate  NGS oncology assays for genomic tumor profiling of plasma and tissue samples.  

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Sponsored by

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.